IL-2 + imiquimod

Trials studying IL-2 + imiquimod

• phase1A MultIceNTER Phase I Peptide VaCcine Trial for the Treatment of H3-Mutated Gliomasactive not recruitingn=15
• phase3Relevance of Imiquimod as Neo-adjuvant Treatment to Reduce Excision Size and the Risk of Intralesional Excision in Lentigo Malignant of the Facecompletedn=259
• phase2Cemiplimab Plus Imiquimod and Laser Therapy As Neoadjuvant Treatment In Cutaneous Basal Cell Carcinomarecruitingn=18
• phase1A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumorsactive not recruitingn=138
• phase3Imiquimod, Fluorouracil, or Observation in Treating HIV-Positive Patients With High-Grade Anal Squamous Skin Lesionscompletedn=91
• phase4Risk of Squamous Cell Carcinoma on Skin Areas Treated With Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5%completedn=485
• phase4Clinical Outcome and Biomarkers for Predicting Immunological Response in Patients Treated with Imiquimodrecruitingn=96
• phase2Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiformecompletedn=74